TFF PHARMACEUTICALS INC (TFFP)
US87241J2033 - Common Stock
Overall TFFP gets a fundamental rating of 3 out of 10. We evaluated TFFP against 194 industry peers in the Pharmaceuticals industry. The financial health of TFFP is average, but there are quite some concerns on its profitability. TFFP is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
TFFP had negative earnings in the past year.
In the past year TFFP has reported a negative cash flow from operations.
In the past 5 years TFFP always reported negative net income.
TFFP had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of TFFP (-204.16%) is worse than 92.19% of its industry peers.
The Return On Equity of TFFP (-329.84%) is worse than 80.21% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -204.16% | ||
| ROE | -329.84% | ||
| ROIC | N/A |
ROA(3y)-128.2%
ROA(5y)-111.66%
ROE(3y)-147.01%
ROE(5y)-124.69%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
TFFP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
TFFP does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TFFP has been reduced compared to 1 year ago.
The number of shares outstanding for TFFP has been reduced compared to 5 years ago.
TFFP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of -24.41, we must say that TFFP is in the distress zone and has some risk of bankruptcy.
TFFP's Altman-Z score of -24.41 is on the low side compared to the rest of the industry. TFFP is outperformed by 88.54% of its industry peers.
There is no outstanding debt for TFFP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -24.41 |
ROIC/WACCN/A
WACC9.07%
2.3 Liquidity
A Current Ratio of 1.63 indicates that TFFP should not have too much problems paying its short term obligations.
The Current ratio of TFFP (1.63) is worse than 71.88% of its industry peers.
A Quick Ratio of 1.63 indicates that TFFP should not have too much problems paying its short term obligations.
TFFP has a Quick ratio of 1.63. This is in the lower half of the industry: TFFP underperforms 65.63% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.63 | ||
| Quick Ratio | 1.63 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 28.62% over the past year.
Looking at the last year, TFFP shows a very strong growth in Revenue. The Revenue has grown by 54.18%.
EPS 1Y (TTM)28.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%65.14%
Revenue 1Y (TTM)54.18%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%95.2%
3.2 Future
The Earnings Per Share is expected to grow by 21.17% on average over the next years. This is a very strong growth
Based on estimates for the next years, TFFP will show a very strong growth in Revenue. The Revenue will grow by 153.49% on average per year.
EPS Next Y65.1%
EPS Next 2Y30.1%
EPS Next 3Y21.17%
EPS Next 5YN/A
Revenue Next Year60.13%
Revenue Next 2Y5.41%
Revenue Next 3Y153.49%
Revenue Next 5YN/A
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
TFFP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TFFP. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as TFFP's earnings are expected to grow with 21.17% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.1%
EPS Next 3Y21.17%
5. Dividend
5.1 Amount
No dividends for TFFP!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TFF PHARMACEUTICALS INC
NASDAQ:TFFP (11/15/2024, 8:00:00 PM)
After market: 0.3896 +0.01 (+3.59%)0.3761
-1.22 (-76.49%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.31M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -204.16% | ||
| ROE | -329.84% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.13
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.63 | ||
| Quick Ratio | 1.63 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)28.62%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y65.1%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)54.18%
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y